[Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects]

[Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects] Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

[Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects] Abstract Text:

Jing Yuan,Bo-ping Zhou,Zuo-jiong Gong,Liu-mei Xu,Xiao-ling Jiang,Masashi Mizokami,

BACKGROUND: To study the relationship between hepatitis B virus genotyping Shenzhen isolates and HBV precore/core promoter mutation and antiviral effects. METHODS: The HBV genotyping of 165 patients with HBV was carried out with mAbs ELISA. HBV precore/core promoter mutation was detected with gene chip technology in 24 patients with CHB. The relationship between HBV genotyping and interferon, lamivudine effects was analyzed. RESULTS: (1) Out of 165 cases, 106 (64.2%) of type B but 48 (29.1%) of type C were found. Type B accounted for 95.4% in group ASC, and type C for 64.7%in group LC (P<0.05). (2) Precore/core promoter mutation was found in 16 cases (10 of type B, and 6 of type C) out of 24 cases. Out of 16 cases, precore/core promoter mutation (nt1896, 1862) was found in 10 cases (9 cases of type B and 1 case of type C), while basal core promoter mutation (BCP mutation, nt1762,1764) was found in 6 cases (1 case of type B and 5 of type C). (3) Among 27 patients with CHB HBAg (+) treated with interferon, 11 cases of type B but 1 case of type C were tested to be fully responsive to interferon. Among 29 patients with CHB HBAg (+) treated with lamivudine, 15 cases of type B but 3 cases of type C were tested to be continuously responsive to lamivudine. CONCLUSION: (1) HBV genotype popularity in Shenzhen area was classified as type B the first and type C the second. (2) Type C seems more apt to develop BCP mutation and cirrhosis, and to be less responsive to interferon or lamivudine.

[Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects] Publishing Authors By Initials

J Yuan,BP Zhou,ZJ Gong,LM Xu,XL Jiang,M Mizokami,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

[Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects] Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Zhonghua shi yan he lin chuang bing du xue za zhi

VOLUME: 20

Page Numbers: 30-2

Journal Abbreviation: Zhonghua Shi Yan He Lin Chuang

ISSN: 1003-9279

DAY: 27

MONTH: Mar

YEAR: 2006

[Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects] Information

Number of References:

LANGUAGE: chi

NlmUniqueID: 9602873

[Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects] Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: [Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects] Information

Substance Name:

Registry Number:

Grant and Affiliation Information for [Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects]

AFFILIATION: Shenzhen East Lake Hospital, Shenzhen 518020, China.

Country: China

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Zhonghua Shi Yan He Lin Chuang

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects Related Publications

• A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C.
• Accidental exposure to HCV antibody-positive blood in hospital and pre-emptive one-shot interferon alpha-2b treatment.
• Characteristics of hepatitis B virus genotype G coinfected with genotype H in chimeric mice carrying human hepatocytes.
• Classification of hepatitis B virus genotype B into 2 major types based on characterization of a novel subgenotype in arctic indigenous populations.
• Comparison of complete sequences of hepatitis B virus genotype C between inactive carriers and hepatocellular carcinoma patients before and after seroconversion.
• Development and public release of a comprehensive hepatitis virus database.
• Differences of HBV genotypes and hepatocellular carcinoma in Asian countries.
• Epidemiological and clinical evaluation of hepatitis B, hepatitis C, and delta hepatitis viruses in Tajikistan.
• Field spread of a diffracted Gaussian beam through a circular aperture.
• Hepatitis B caused by a hepatitis B surface antigen escape mutant.
• Hepatitis B virus transmission pattern and vaccination efficiency in Uzbekistan.
• Impact of daily high-dose IFNalpha-2b plus ribavirin combination therapy on reduction of ALT levels in patients with chronic hepatitis C with genotype 1 and high HCV RNA levels.
• Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2.
• Long-term efficacy of preoperative radiotherapy for locally advanced low rectal cancer.
• Pelvic drainage for anterior resection revisited: use of drains in anastomotic leaks.
• Purification and cDNA cloning of a novel protease inhibitor secreted into culture supernatant by MDCK cells.
• Retroposition of the mandible in complete denture wearers.
• Suppressive effect of oral administration of branched-chain amino acid granules on oxidative stress and inflammation in HCV-positive patients with liver cirrhosis.
• Tracing hepatitis C and Delta viruses to estimate their contribution in HCC rates in Mongolia.
• Transmission of hepatitis B virus (HBV) genotypes among Japanese immigrants and natives in Bolivia.
• Two subtypes (subgenotypes) of hepatitis B virus genotype C: A novel subtyping assay based on restriction fragment length polymorphism.
• Tympanic membrane temperature in a patient with vertigo.
• Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia.
• When should "i" consider a new hepatitis B virus genotype?
• [Predicting sustained virological response in chronic hepatitis C patients treated with pegylated interferon and ribavirin using a novel highly sensitive Real-time detection PCR assay]
• [Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects]